Examining the biological causes of eating disorders to inform treatment strategies por Walter Suárez Carmona | Jun 23, 2025
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes por Walter Suárez Carmona | Jun 23, 2025
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes por Walter Suárez Carmona | Jun 23, 2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity por Walter Suárez Carmona | Jun 23, 2025
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial por Walter Suárez Carmona | Jun 23, 2025
